Disproportionate regulation of European clinical trials is hampering research

<![CDATA[

Top medical research organisations are calling on the European Union for urgent reforms to the way clinical trials are regulated across the continent.

Disproportionate regulation of European clinical trials is hampering research into potentially lifesaving treatments – without enhancing patient safety – according to sixteen organisations* including Cancer Research UK, the Academy of Medical Sciences, the British Heart Foundation, the Wellcome Trust and the European Science Foundation.

Their statement to the European Commission and Members of the European Parliament (MEPs) outlines how the European Clinical Trials Directive – which sets out the legal requirements for conducting clinical trials throughout the European Union – should be revised to help streamline the approval process for clinical trials.

The Directive is interpreted differently throughout Europe with evidence that those undertaking trials go above and beyond the requirements to ensure they are compliant. This can cause unnecessary bureaucracy and makes it increasingly difficult for researchers to undertake multi-national trials.

Ref and Read more: http://www.ecancermedicalscience.com/news-insider-news.asp?itemId=2015

]]>